We are live on ! Find out more
IMGN

Immunogen Inc

Delisted

IMGN was delisted on the 9th of February, 2024.

189 hedge funds and large institutions have $252M invested in Immunogen Inc in 2019 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 54 increasing their positions, 61 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

417% more call options, than puts

Call options by funds: $2.46M | Put options by funds: $476K

14% more capital invested

Capital invested by funds: $221M → $252M (+$30.2M)

10% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 31

2% less funds holding

Funds holding: 192189 (-3)

11% less repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 61

Holders
189
Holders Change
-3
Holders Change %
-1.56%
% of All Funds
4.14%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
28
Increased
54
Reduced
61
Closed
31
Calls
$2.46M
Puts
$476K
Net Calls
+$1.99M
Net Calls Change
+$375K
Name Holding Trade Value Shares
Change
Change in
Stake
VF
76
Virtu Financial
New York
$166K -$44.9K -16,909 -20%
Voloridge Investment Management
77
Voloridge Investment Management
Florida
$166K +$182K +68,561 New
Janney Montgomery Scott
78
Janney Montgomery Scott
Pennsylvania
$152K -$36K -13,577 -18%
GC
79
Grace Capital
Massachusetts
$149K -$26.6K -10,000 -14%
VOYA Investment Management
80
VOYA Investment Management
Georgia
$145K
MIM
81
MetLife Investment Management
New Jersey
$145K
ProShare Advisors
82
ProShare Advisors
Maryland
$138K -$4.66K -1,754 -3%
Commonwealth Equity Services
83
Commonwealth Equity Services
Massachusetts
$135K +$112K +42,213 +304%
CM
84
Caption Management
Oklahoma
$121K -$79.7K -30,000 -38%
MLICM
85
Metropolitan Life Insurance Company (MetLife)
New York
$118K
MTIM
86
Marathon Trading Investment Management
Pennsylvania
$109K +$60.5K +22,800 +103%
Principal Financial Group
87
Principal Financial Group
Iowa
$100K +$10.2K +3,823 +10%
Wolverine Trading
88
Wolverine Trading
Illinois
$92K +$26.2K +9,853 +41%
Legal & General Group
89
Legal & General Group
United Kingdom
$91K +$29.3K +11,045 +42%
NFC
90
Northeast Financial Consultants
Connecticut
$83K
TRCT
91
Tower Research Capital (TRC)
New York
$81K +$88.6K +33,378 New
LPL Financial
92
LPL Financial
California
$79K -$3.69K -1,391 -4%
SI
93
Stephens Inc
Arkansas
$67K -$2.49K -939 -3%
Victory Capital Management
94
Victory Capital Management
Texas
$61K +$66.5K +25,037 New
AB
95
Amalgamated Bank
New York
$57K -$576 -217 -0.9%
BNP Paribas Financial Markets
96
BNP Paribas Financial Markets
France
$55.5K +$18.8K +7,064 +45%
MML Investors Services
97
MML Investors Services
Massachusetts
$52K -$21.9K -8,239 -28%
Ameriprise
98
Ameriprise
Minnesota
$50K +$55.1K +20,748 New
AT
99
Arden Trust
Delaware
$49K -$491 -185 -0.9%
Public Employees Retirement Association of Colorado
100
Public Employees Retirement Association of Colorado
Colorado
$47K

IMGN Hedge Fund Activity: Q3 2019 in Review

189 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q3 2019, worth a combined $252M — up 14% from $221M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of IMGN and 28 opened new positions — a net loss of 3 holders — while 61 trimmed existing stakes and 54 added.

The largest buyer was Vanguard Group, adding an estimated $8.71M. The largest seller was Morgan Stanley, cutting an estimated $8.2M.

  • 189 institutional investors held Immunogen Inc (IMGN) as of Q3 2019, down from 192 in Q2 2019.
  • Funds reported $252M of Immunogen Inc stock for Q3 2019, up 14% quarter-over-quarter.
  • 28 funds opened new Immunogen Inc positions in Q3 2019 and 31 closed out, a net change of -3 holders.
  • The largest Immunogen Inc buyer in Q3 2019 was Vanguard Group, an estimated $8.71M added.
  • The largest Immunogen Inc seller in Q3 2019 was Morgan Stanley, an estimated $8.2M sold.

Based on aggregated 13F filings for Q3 2019.